PE53097A1 - Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos - Google Patents

Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos

Info

Publication number
PE53097A1
PE53097A1 PE1996000254A PE00025496A PE53097A1 PE 53097 A1 PE53097 A1 PE 53097A1 PE 1996000254 A PE1996000254 A PE 1996000254A PE 00025496 A PE00025496 A PE 00025496A PE 53097 A1 PE53097 A1 PE 53097A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
compounds
arilglycinamide
procedures
Prior art date
Application number
PE1996000254A
Other languages
English (en)
Inventor
Hans Briem
Gerd Schnorrenberg
Franz Esser
Horst Dollinger
Birgit Jung
Georg Speck
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of PE53097A1 publication Critical patent/PE53097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS ANTAGONISTAS DE NEUROQUININAS (TAQUIQUININA) DE FORMULA (I), DONDE: Ar ES FENILO SUSTITUIDO CON -OCH2-O- o -O(CH2)2-O- o ES (FENILO O NAFTILO) CON SUSTITUCIONES OPCIONALES DE HALOGENO, OH, ALQUILO C1-C4, O-ALQUILO C1-C4, CF3 o NR9R10 (R9 Y R10 SON H, CH3 o ACETILO); R1 Y R2, EN COMUN CON EL N AL QUE ESTAN UNIDOS FORMAN UN ANILLO DE FORMULA (II) DONDE p ES 2 o 3; X ES O, N(CH2)nR6 o CR7R8; n ES 0, 1 o 2; R6 ES CICLOALQUILO C3-C7 o (FENILO O NAFTILO CON 1, 2 o 3 SUSTITUCIONES OPCIONALES MENCIONADOS EN Ar); R7 Y R8 FORMAN UN RADICAL COMUN CH3-C0NH-CH2-N(CH3)-FENILO O R7 ES H (SI R3 ES FENILO) O R7 ES FENILO o PIPERIDINILO, ENTRE OTROS (SI R8 ES H, CO-NH2 O NH-CO-CH3, ENTRE OTROS); R3 ES H o FENILALQUILO C1-C4, ENTRE OTROS, PREFERENTEMENTE ES FENILALQUILO C1-C3 CON 2 SUSTITUYENTES CF3; R5 ES H, ALQUILO C1-C4 o CH2CONH2, ENTRE OTROS. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DEL COMPUESTO (I), QUE COMPRENDE: a) HACER REACCIONAR NR1R2-C(R3)(Ar)-COOH (SU HALOGENURO O ESTER), CON HN(R4)(R5); b) HACER REACCIONAR UNA O-HALOGENO-ARILACETAMIDA CON UNA AMINA; o c) ALQUILAR EN N, UN COMPUESTO (I), DONDE R5 ES H; FINALMENTE AISLARLO COMO COMPUESTO LIBRE O COMO SAL FARMACEUTICAMENTE ACEPTABLE
PE1996000254A 1995-04-14 1996-04-11 Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos PE53097A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19514112 1995-04-14
DE19519245A DE19519245C2 (de) 1995-04-14 1995-05-25 Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
PE53097A1 true PE53097A1 (es) 1998-01-20

Family

ID=7759690

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000254A PE53097A1 (es) 1995-04-14 1996-04-11 Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos

Country Status (12)

Country Link
US (3) US5710155A (es)
KR (1) KR100459746B1 (es)
AR (1) AR004662A1 (es)
CO (1) CO4700439A1 (es)
DE (2) DE19519245C2 (es)
EG (1) EG24080A (es)
MY (1) MY114548A (es)
PE (1) PE53097A1 (es)
SA (1) SA96170225B1 (es)
UA (1) UA46765C2 (es)
YU (1) YU49418B (es)
ZA (1) ZA962916B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413959B1 (en) 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
TW449590B (en) 1995-04-14 2001-08-11 Boehringer Ingelheim Kg New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
DE19608665A1 (de) * 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) * 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6057338A (en) * 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) * 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
JP2001523226A (ja) 1997-04-14 2001-11-20 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
EP0975625A1 (en) * 1997-04-14 2000-02-02 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998046627A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
JP2001521524A (ja) * 1997-04-14 2001-11-06 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6117880A (en) * 1997-10-30 2000-09-12 Merck & Co., Inc. Somatostatin agonists
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6387932B1 (en) 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
US6355801B1 (en) 1999-11-08 2002-03-12 Schering Corporation Process for preparing N-(4-hydroxyphenyl)-N′-(4′-aminophenyl)-piperazine
AR037364A1 (es) * 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
AU2005214159A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518274A (en) * 1967-10-09 1970-06-30 Miles Lab Phenyl substituted n-(2-aminoethyl)-n-benzylamides
US3862946A (en) * 1973-05-24 1975-01-28 Miles Lab N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)ethyl{9 {0 propionamide para-chlorobenzene sulfonate
US3906100A (en) * 1973-05-24 1975-09-16 Miles Lab N-benzyl-N-{8 2-phenyl-2-(4-phenyl-1-piperidyl)-ethyl{9 -propionamide para-chlorobenzene sulfonate
WO1994001402A1 (en) * 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
GB9221931D0 (en) * 1992-10-17 1992-12-02 Wyeth John & Brother Ltd Piperazine derivatives
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
US5696123A (en) * 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists

Also Published As

Publication number Publication date
US5861509A (en) 1999-01-19
KR100459746B1 (ko) 2005-05-31
YU22996A (sh) 1998-12-23
DE19519245C2 (de) 2003-04-30
EG24080A (en) 2008-05-11
AR004662A1 (es) 1999-03-10
DE59611204D1 (de) 2005-04-07
CO4700439A1 (es) 1998-12-29
US6121262A (en) 2000-09-19
UA46765C2 (uk) 2002-06-17
US5710155A (en) 1998-01-20
KR19980703760A (ko) 1998-12-05
SA96170225B1 (ar) 2006-07-31
DE19519245A1 (de) 1996-10-17
MY114548A (en) 2002-11-30
ZA962916B (en) 1996-10-14
YU49418B (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
PE53097A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
NO955074L (no) 1-substituerte istain- og oksindolderivater som inhibitorer til acetylkolinesterase
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
NO942316L (no) Isatinderivater, fremgangsmåter for deres fremstilling og farmasöytisk preparat omfattende slike derivater
AR038235A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
ES2061204T3 (es) Nuevos derivados de la amino-piperidina, de la amino-pirrolidina y de la amino-perhidroacepina, procedimientos de preparacion y composiciones farmaceuticas que los contienen.
CO4920223A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8- sustituidos
FI831009L (fi) Spiro/4(3+n)/-2-aza-3-karboxylsyra-derivat, foerfarande foer deras framstaellning, dessa innehaollaaemnen och deras anvaendning
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
NZ307505A (en) Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds
AR041246A1 (es) Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
UY24429A1 (es) Acetidinas
DE69133295D1 (de) 3,9-diazabicyclo-[3.3.1]-nonanylderivate, verfahren und intermediate für ihre darstellung und sie enthaltende pharmazeutische zusammensetzungen
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
ES2106936T5 (es) Derivados de carbazolona y procedimientos para su preparacion.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
PE20232044A1 (es) Compuestos heterociclicos de heteroarilo y usos de los mismos
AR008168A1 (es) Compuestos etilamino arilamida aril substituidos de pirrolidinilo y pirrolinilo, composicion farmaceutica que lo contiene, compuesto util para susintesis, procedimiento para su preparacion
NO20006350L (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
KR940011412A (ko) α,ω-디아릴알칸 유도체, 그의 제조방법, 및 순환계 질환 및 정신병의 치료 및 예방용 용도.
AR002715A1 (es) Derivados de piperazina y piperazinona heterociclos substituidos particularmente utiles como antagonistas de los receptores de taquikinina,composicion farmaceutica que incluye uno de dichos derivados, uso de dichos compuestos en la preparacion de las composiciones y procedimiento para la preparacion de los derivados

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed